Background Acute myeloid leukemia (AML) pathogenesis
and treatment are currently being better understood at
an accelerated rate. Determining genetic and epigenetic
changes that can identify patients who are at risk of poor
outcomes is therefore desired to optimize treatment options.
Many solid tumors have been reported to overexpress
Inhibitors of DNA binding proteins (ID1), but few research
has looked at the clinical significance of ID1 expression
in AML. Additionally, little research has been focused on
the direct role of ID4 in myeloid malignancies, as well as
its expression and methylation patterns. The aim of the
current study was to assess ID1 and ID4 gene expression
in bone marrow (BM) aspiration specimens of 91 AML
patients, compared with 14 control donors of bone marrow
transplantation (BMT), using real-time polymerase chain
reaction (RT-PCR). Data were correlated with patients’
clinicopathological features, response to treatment, diseasefree
survival (DFS), and overall survival (OS) rates. |
